| Medical and Health Sciences | 2021-2025 | 61 | GB 6 | 99.99 |
| Pulmonary and Respiratory Medicine | Lifetime | 119 | GB 11 | 99.84 |
| Epidemiology | Lifetime | 360 | GB 29 | 99.57 |
| Emergency Medical Services | Lifetime | 361 | GB 33 | 96.67 |
| Emergency Medicine | Lifetime | 911 | GB 80 | 88.51 |
| Critical Care and Intensive Care Medicine | Lifetime | 523 | GB 38 | 85.75 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 9 | GB 1 | 99.97 |
| Epidemiology | 2021-2025 | 131 | GB 11 | 99.17 |
| Emergency Medical Services | 2021-2025 | 21 | GB 2 | 98.30 |
| Infectious Diseases | 2021-2025 | 590 | GB 54 | 86.72 |
| Medical Physiology | 2021-2025 | 853 | GB 75 | 85.84 |
| Immunology | 2021-2025 | 630 | GB 31 | 81.53 |
| Tracheal and airway disorders | Lifetime | 8 | GB 2 | 99.87 |
| Cystic Fibrosis Research Advances | Lifetime | 6 | GB 2 | 99.77 |
| Neonatal Respiratory Health Research | Lifetime | 34 | GB 4 | 99.77 |
| Pneumonia and Respiratory Infections | Lifetime | 50 | GB 6 | 99.71 |
| Respiratory viral infections research | Lifetime | 93 | GB 9 | 99.51 |
| Pediatric health and respiratory diseases | Lifetime | 76 | GB 15 | 99.35 |
| Emergency and Acute Care Studies | Lifetime | 115 | GB 12 | 99.05 |
| Chronic Obstructive Pulmonary Disease (COPD) Research | Lifetime | 184 | GB 29 | 99.23 |
| Long-Term Effects of COVID-19 | Lifetime | 339 | GB 42 | 97.25 |
| Nosocomial Infections in ICU | Lifetime | 115 | GB 2 | 98.84 |
| Pneumocystis jirovecii pneumonia detection and treatment | Lifetime | 393 | GB 36 | 97.89 |
| Respiratory and Cough-Related Research | Lifetime | 355 | GB 59 | 97.96 |
| Sepsis Diagnosis and Treatment | Lifetime | 614 | GB 37 | 97.42 |
| Dysphagia Assessment and Management | Lifetime | 765 | GB 54 | 94.53 |
| Neutrophil, Myeloperoxidase and Oxidative Mechanisms | Lifetime | 898 | GB 76 | 93.50 |
| Neonatal Respiratory Health Research | 2021-2025 | 1 | GB 1 | 99.97 |
| Tracheal and airway disorders | 2021-2025 | 1 | GB 1 | 99.98 |
| Cystic Fibrosis Research Advances | 2021-2025 | 1 | GB 1 | 99.98 |
| Pediatric health and respiratory diseases | 2021-2025 | 1 | GB 1 | 99.87 |
| Respiratory viral infections research | 2021-2025 | 14 | GB 3 | 99.60 |
| Pneumonia and Respiratory Infections | 2021-2025 | 30 | GB 4 | 98.99 |
| Chronic Obstructive Pulmonary Disease (COPD) Research | 2021-2025 | 62 | GB 13 | 98.88 |
| Long-Term Effects of COVID-19 | 2021-2025 | 154 | GB 33 | 98.13 |
| Neutrophil, Myeloperoxidase and Oxidative Mechanisms | 2021-2025 | 22 | GB 2 | 96.11 |
| COVID-19 Clinical Research Studies | 2021-2025 | 794 | GB 93 | 96.71 |
| Respiratory Support and Mechanisms | 2021-2025 | 373 | GB 34 | 95.91 |
| Asthma and respiratory diseases | 2021-2025 | 371 | GB 47 | 96.64 |
| Peptidase Inhibition and Analysis | 2021-2025 | 409 | GB 15 | 92.53 |
| Pneumocystis jirovecii pneumonia detection and treatment | 2021-2025 | 257 | GB 22 | 89.87 |
| Respiratory and Cough-Related Research | 2021-2025 | 217 | GB 32 | 92.47 |
| Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis | 2021-2025 | 556 | GB 41 | 91.59 |
| Nosocomial Infections in ICU | 2021-2025 | 477 | GB 23 | 78.15 |
| Protease and Inhibitor Mechanisms | 2021-2025 | 249 | GB 10 | 79.63 |
| Oral and Craniofacial Lesions | 2021-2025 | 57 | GB 4 | 77.58 |
| Delphi Technique in Research | 2021-2025 | 942 | GB 244 | 64.30 |
| Inflammation biomarkers and pathways | 2021-2025 | 637 | GB 14 | 22.14 |
